Beite pharmaceuticals IPO acceptance will usher in more development opportunities

category:Finance
 Beite pharmaceuticals IPO acceptance will usher in more development opportunities


Beite pharmaceutical has 6 production bases in Chengdu, Haikou and Guangan in China, including 4 preparation production bases and 2 API production bases. At present, it has several GMP certified production lines covering tablets, granules, capsules, dry suspension, powder injection, freeze-dried powder injection, small volume injection, large volume injection, etc, Several production lines, such as inhalation aerosol, inhalation powder spray, aerosol inhalation agent and nasal spray, have been completed. Among them, the companys API production base has the only ampicillin sodium API workshop which has passed the GMP certification of EU and Japan. According to the prospectus (application draft), in 2017, 2018 and 2019, the operating revenue of Beite pharmaceutical was 1125.4315 million yuan, 2531.6338 million yuan and 3236.3949 million yuan, respectively; the net profit attributable to the parent company was 140.2863 million yuan, 27.911.56 million yuan, 223.6506 million yuan; the proportion of R & D investment in business income was 11.08%, 8.35% and 12.20% respectively. Source: editor in charge of mass news: Chen Tiqiang_ NB6485

Beite pharmaceutical has 6 production bases in Chengdu, Haikou and Guangan in China, including 4 preparation production bases and 2 API production bases. At present, it has several GMP certified production lines covering tablets, granules, capsules, dry suspension, powder injection, freeze-dried powder injection, small volume injection, large volume injection, etc, Several production lines, such as inhalation aerosol, inhalation powder spray, aerosol inhalation agent and nasal spray, have been completed. Among them, the companys API production base has the only ampicillin sodium API workshop which has passed the GMP certification of EU and Japan.

According to the prospectus (application draft), in 2017, 2018 and 2019, the operating revenue of Beite pharmaceutical was 1125.4315 million yuan, 2531.6338 million yuan and 3236.3949 million yuan, respectively; the net profit attributable to the parent company was 140.2863 million yuan, 27.911.56 million yuan, 223.6506 million yuan; the proportion of R & D investment in business income was 11.08%, 8.35% and 12.20% respectively.